论文部分内容阅读
目的研究美沙拉嗪联合双歧杆菌四联活菌在治疗溃疡性结肠炎中的临床效果。方法选取50例溃疡性结肠炎病人,分为2组,试验组27例,给予美沙拉嗪及双歧杆菌四联活菌;对照组23例,给予美沙拉嗪。观察2组患者治愈率及治疗前后的患者血清中白细胞介素-8(IL-8)水平。结果试验组治愈率(92.6%)明显高于对照组(78.3%),经比较差异有统计学意义(P<0.05),试验组和对照组治疗14 d后,IL-8水平明显低于治疗前,两者相比,差异有统计学意义(P<0.05)。结论美沙拉嗪联合双歧杆菌四联活菌可提高溃疡性结肠炎的治愈率,且不良反应少,为临床治疗提供思路。
Objective To study the clinical efficacy of mesalazine combined with bifidobacterium viable bacteria in the treatment of ulcerative colitis. Methods Fifty patients with ulcerative colitis were selected and divided into two groups. The experimental group was given 27 cases of mesalazine and Bifidobacterium quadruliformis. The control group was given mesalazine. The cure rate of patients in two groups and the level of interleukin-8 (IL-8) in serum of patients before and after treatment were observed. Results The cure rate of experimental group (92.6%) was significantly higher than that of control group (78.3%), the difference was statistically significant (P <0.05). After 14 days of treatment, the level of IL-8 in experimental group and control group was significantly lower than that of treatment group Before the two, the difference was statistically significant (P <0.05). Conclusion Mesalazine combined with Bifidobacterium quadriceps can improve the cure rate of ulcerative colitis with less adverse reactions, providing the idea for clinical treatment.